BioSpace News Archive

The data showed that Tresiba® (insulin degludec injection) U-100 had no increased risk of MACE compared to insulin glargine U-100 in patients with type 2 diabetes and ASCVD1; Tresiba® U-100 becomes the first and only long-acting insulin to have demonstrated significantly lower rates of severe hypoglycemia versus insulin glargine U-100 in adult patients with type 2 diabetes and ASCVD1,2,3,4,5,6,7,8

Bold Growth Inc. has officially broken ground on its 56,018 square-foot cultivation and processing facility on the outskirts of Saskatoon, SK.

RXi Pharmaceuticals Corporation reported its financial results for the fourth quarter and year ended December 31, 2017 and provided a business update.

A San Antonio jury today returned a unanimous verdict in favor of Allergy & Asthma Network, the defendant in a federal antitrust lawsuit brought by United Allergy Services in early 2014.

Kaiser Permanente Washington welcomes Tim Shriver, international chairman of the board of directors for Special Olympics, and the Washington team of 247 Special Olympics athletes for a send-off celebration Tuesday.

Bayer announced that its collaboration partner Loxo Oncology, Inc., has completed the rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for larotrectinib for the treatment of adult and pediatric patients.

BIOREM Inc. announced its results for the three and twelve-month periods ended December 31, 2017.

Ionis Pharmaceuticals, Inc. and Akcea Therapeutics, Inc. announced Phase 3 data showing that inotersen-treated patients with hereditary ATTR (hATTR) amyloidosis who were treated for up to 27 months in the NEURO-TTR and open-label extension (OLE) studies continued to demonstrate sustained benefit in measures of quality of life and neuropathy.

Offering ‘one connection, complete control’ through simplified data management, ORTHO CONNECT V2.0 is now commercially available in the United States

NDA includes data from two successful Phase 3 trials in HSDD in premenopausal women in which bremelanotide met the pre-specified co-primary efficacy endpoints